digest
Short Summary
Main recommendation: Dr. Ahmet Ergin advises that if diabetes requires medication, patients should consider moving away from sulfonylureas (glipizide, glyburide, glimepiride) toward agents with fewer side effects, such as GLP-1 class drugs, metformin, pioglitazone, or acarbose. He argues that sulfonylureas are common mainly because they are inexpensive and widely available, not because they are the best option.
Key Points
- Sulfonylureas work by stimulating pancreatic beta cells to produce insulin continuously, regardless of whether food is eaten, which raises the risk of low blood sugar and weight gain.
- Sulfonylureas are cleared by the kidneys and can accumulate in people with even early kidney disease, making severe, hard-to-reverse low blood sugar more likely.
- Dr. Ergin cites studies comparing sulfonylureas with insulin sensitizers in which sulfonylurea users needed insulin sooner; he gives a rough illustration of 100 patients, with about 10 doing fine indefinitely, about 50 needing insulin within 5 to 10 years, and about 40 needing it within a few years.
- The GLP-1 class (semaglutide/Ozempic/Rybelsus, liraglutide/Victoza, dulaglutide/Trulicity) stimulates insulin only when needed, slows glucose absorption, reduces appetite, and promotes weight loss, the opposite of sulfonylureas.
- Dr. Ergin says GLP-1 agents can reduce inappropriate glucagon release after meals and may preserve beta cell function; he cites a semaglutide study where insulin response became nearly identical to people without diabetes after about 12 weeks, and says he has had patients reach an A1c around 5% on this class, though he does not call this a guaranteed outcome.
Details Worth Noting
- Concrete instructions: Dr. Ergin notes that sulfonylureas are typically taken before breakfast, and if a meal is skipped, blood sugar can drop since insulin is released regardless of food intake; he suggests discussing alternatives such as metformin, pioglitazone, acarbose, or a GLP-1 agent with your doctor, including cost-reduction options, and mentions that kidney problems can cause these drugs to accumulate. He emphasizes not changing medication without consulting your doctor.
- Shorter-acting sulfonylureas (gliclazide, glipizide) act for roughly seven to eight hours, versus longer-acting glyburide and glimepiride, though the speaker says all still cause weight gain and low blood sugar.
- Acarbose causes significant gas and intestinal discomfort; metformin also has gastrointestinal side effects, which the speaker says he will cover in another video.
- Pioglitazone has no immediate side effects but may raise fracture risk with prolonged use, especially in elderly women; a small bladder cancer risk was suggested but involved very few cases.
- The speaker notes GLP-1 drugs are expensive but says copay coupons and pharmacist help may reduce costs; injections are a barrier for some patients, though GLP-1 drugs are not insulin.
- The speaker says sulfonylureas remain reasonable when cost is a barrier or when a patient is satisfied and doing well, and emphasizes that individual responses vary.
Bottom Line
Sulfonylureas carry a real risk of low blood sugar, weight gain, and possible long-term beta cell strain, so patients on them should discuss safer alternatives with their doctor, while weighing cost, kidney function, and personal response.
